- No file added yet -

Supplementary Tables – Efficacy and Safety of First-Line Therapies in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis

dataset

posted on 2022-02-21, 12:36 authored by Taylor & FrancisTaylor & Francis, Katrin Haeussler, Xuan Wang, Katherine B Winfree, Yulia D'yachkova, Sory Traore, Tarun Puri, Howard Thom, Christos Papagiannopoulos, Maria Nassim, Kaisa Taipale

Table A1. Full search strategy for Embase.

Table A2. Full search strategy for MEDLINE.

Table A3. Full search strategy for Cochrane.

Table A4. Trials identified from the SLR (n=57).

Table A5. PFS evidence for overall EGFRm+ NSCLC patient population, by mutation type, and by geographical region.

Table A6. OS evidence for overall EGFRm+ NSCLC patient population.

Table A7. Base case PFS - pairwise comparisons of all interventions and comparators.

Table A8. Base case OS - pairwise comparisons of all interventions and comparators.

Funding

Eli Lilly & Co.,IN, USA

History

Usage metrics

Keywords

EGFR positive network meta-analysis systematic literature review non-small-cell lung cancer progression-free survival tyrosine kinase inhibitors Cancer Therapy (excl. Chemotherapy and Radiation Therapy)Solid Tumours

Licence

CC BY-NC-ND 4.0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM